Kenneth W Hance
Overview
Explore the profile of Kenneth W Hance including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valenzuela-Vazquez L, Nunez-Enriquez J, Sanchez-Herrera J, Medina-Sanson A, Perez-Saldivar M, Jimenez-Hernandez E, et al.
Front Oncol
. 2022 Nov;
12:1023510.
PMID: 36419901
NK cells have unique attributes to react towards cells undergoing malignant transformation or viral infection. This reactivity is regulated by activating or inhibitory germline encoded receptors. An impaired NK cell...
2.
Torres N, Regge M, Secchiari F, Friedrich A, Spallanzani R, Raffo Iraolagoitia X, et al.
J Immunother Cancer
. 2020 Jun;
8(1).
PMID: 32518090
Background: Natural killer and cytotoxic CD8 T cells are major players during antitumor immunity. They express NKG2D, an activating receptor that promotes tumor elimination through recognition of the MHC class...
3.
Mayes P, Hance K, Hoos A
Nat Rev Drug Discov
. 2018 Jun;
17(7):509-527.
PMID: 29904196
Immune cell functions are regulated by co-inhibitory and co-stimulatory receptors. The first two generations of cancer immunotherapy agents consist primarily of antagonist antibodies that block negative immune checkpoints, such as...
4.
Lan Y, Zhang D, Xu C, Hance K, Marelli B, Qi J, et al.
Sci Transl Med
. 2018 Jan;
10(424).
PMID: 29343622
Antibodies targeting immune checkpoints are emerging as potent and viable cancer therapies, but not all patients respond to these as single agents. Concurrently targeting additional immunosuppressive pathways is a promising...
5.
Waight J, Takai S, Marelli B, Qin G, Hance K, Zhang D, et al.
J Immunol
. 2014 Dec;
194(3):878-82.
PMID: 25548231
CD4(+) regulatory T cells (Tregs) are critical for maintaining self-tolerance and function to prevent autoimmune disease. High densities of intratumoral Tregs are generally associated with poor patient prognosis, a correlation...
6.
Brown D, Hance K, Rogers C, Sansbury L, Albert P, Murphy G, et al.
Cancer Epidemiol Biomarkers Prev
. 2011 Dec;
21(2):337-46.
PMID: 22144502
Background: Macrophage inhibitory cytokine-1 (MIC-1/GDF15) mediates nonsteroidal anti-inflammatory drug (NSAID) protection from colonic polyps in mice and is linked to the development of colorectal carcinoma in humans. Therefore, changes in...
7.
Vergati M, Cereda V, Madan R, Gulley J, Huen N, Rogers C, et al.
Cancer Immunol Immunother
. 2010 Oct;
60(2):197-206.
PMID: 20976449
We have previously shown that the suppressive function of regulatory T cells (Tregs) from peripheral blood mononuclear cells (PBMCs) is enhanced in patients with prostate cancer when compared with healthy...
8.
Zaharoff D, Hance K, Rogers C, Schlom J, Greiner J
J Immunother
. 2010 Jul;
33(7):697-705.
PMID: 20664357
IL-12 is a potent antitumor cytokine that exhibits significant clinical toxicities after systemic administration. We hypothesized that intratumoral (i.t.) administration of IL-12 coformulated with the biodegradable polysaccharide chitosan could enhance...
9.
Bobe G, Murphy G, Rogers C, Hance K, Albert P, Laiyemo A, et al.
Cancer Epidemiol Biomarkers Prev
. 2010 May;
19(6):1441-52.
PMID: 20501764
Background: Serum adiponectin, leptin, C-peptide, and homocysteine are indicators for obesity, hyperinsulinemia, and chronic inflammation, which have all been associated with colorectal cancer. Aims: To determine whether serum adiponectin, leptin,...
10.
Zaharoff D, Hoffman B, Hooper H, Benjamin Jr C, Khurana K, Hance K, et al.
Cancer Res
. 2009 Jul;
69(15):6192-9.
PMID: 19638573
Intravesical BCG has been used successfully to treat superficial bladder cancer for three decades. However, 20% to 30% of patients will fail initial BCG therapy and 30% to 50% of...